None
Quote | Immunic Inc. (NYSE:IMUX)
Last: | $ |
---|---|
Change Percent: | 2.18% |
Open: | $8.72 |
Close: | $8.91 |
High: | $8.9799 |
Low: | $8.5022 |
Volume: | 4,415 |
Last Trade Date Time: | 02/12/2020 04:41:22 pm |
News | Immunic Inc. (NYSE:IMUX)
2024-04-12 11:34:12 ET More on S&P 500 Index: Sticking With The More Optimistic View Where We Stand Sorry Campers, The Fed Is Not Riding To The Rescue Nasdaq, S&P, Dow slip as major banks kick off earnings season Nasdaq, S&P climb, Dow end...
2024-04-05 13:00:48 ET More on Immunic Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Immunic Historical earnings data for Immunic Financial information for Immunic Read the full article on Seeking Alpha...
Message Board Posts | Immunic Inc. (NYSE:IMUX)
Subject | By | Source | When |
---|---|---|---|
$IMUX MomentumIts now last trade up | subslover | investorshub | 06/27/2023 10:47:22 PM |
must see | luckydude777 | investorshub | 06/27/2023 1:25:48 PM |
Price trading up | masterofdisaster | investorshub | 06/26/2023 5:08:57 PM |
$IMUX short data if anyone is interested | 81vette | investorshub | 06/23/2023 3:54:37 PM |
$IMUX must see | 81vette | investorshub | 06/23/2023 8:26:34 AM |
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
Immunic to Host MS R&D Day and Participate in Investor Conferences in April Immunic to Host MS R&D Day and Participate in Investor Conferences in April PR Newswire NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a b...
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical n...
--News Direct-- Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application, marking a significant step in the company's intellectual property (IP) strategy. ...